Oxford BioTherapeutics appoints Dr Jim Cornett, Dr Jon Terrett and Dr Mike Gresser
pharmafile | December 2, 2009 | Appointment | Research and Development | Oxford Biotherapeutics, appointment, research and development
Oxford BioTherapeutics has expanded its US operations, recruiting a number of senior industry leaders.
Dr Jim Cornett will head up operations at the company’s California R&D facility as chief operating officer following decades of mAb industry experience at some of the most successful companies in the field, including Medarex, PDL and Centocor.
Jim Cornett said: “I am delighted to be joining Oxford BioTherapeutics at this exciting time in the company’s development. I am highly impressed by what OBT has accomplished so far and I am looking forward to helping the company build on this foundation and grow into a global leader in the oncology mAb sector.”
OBT has also appointed Dr Jon Terrett as VP Oncology. Dr Terrett, joins OBT after several years at Medarex (recently acquired by BMS), where he gained significant experience in the development of oncology biologics.
He has taken multiple oncology mAb programmes from target discovery through to the clinic during his more than ten years experience in the biotech and pharma industry.
In his new role Dr Terrett will head the team of talented scientists at the company’s facility in San Jose. Jim Cornett and Jon Terrett will join forces with Oxford BioTherapeutics’ chief scientific officer, Dr Mike Gresser.
Dr Gresser recently took over the role of CSO after working on the company’s scientific advisory board since early 2007. Prior to joining OBT Mike Gresser worked at Amgen where he was VP Research for Inflammation for six years.
Oxford BioTherapeutics chief executive Dr Christian Rohlff said: “This is a very exciting milestone for the whole company and we are very fortunate to assemble such a high-calibre team of experienced industry leaders to drive the expansion of our US preclinical operations.
“Mike Gresser has already brought immense value to the company as a member of the OBT’s scientific advisory board and more recently since his more active involvement as CSO.
“It is also a strong endorsement of the company’s exciting future that experienced and respected industry experts such as Jim Cornett and Jon Terrett are joining us. I have little doubt that they will accelerate OBT’s efforts to build a successful antibody pipeline that transforms the treatment options for cancer patients.”
The US team will focus on developing OBT’s antibody programmes, which originated at its Oxford, UK-based discovery operation.
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …
